06:44 AM EDT, 08/14/2025 (MT Newswires) -- Aquestive Therapeutics ( AQST ) said Thursday that it has entered a $75 million funding deal with funds managed by RTW Investments, subject to US Food and Drug Administration approval of Anaphylm Sublingual Film and other conditions.

The commercial launch financing will be available once the FDA approves the sublingual epinephrine film and certain refinancing and debt-related requirements are met, the company said.

RTW will receive a tiered single-digit percentage of annual US net sales of Anaphylm for type I allergic reactions, including anaphylaxis, subject to a cap, Aquestive said.

Shares of Aquestive were up more than 9% in recent Thursday premarket activity.